Efficacy and safety of camrelizumab combined with oxaliplatin and S‐1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II, single‐arm study

Documenti analoghi

• Phase II study of perioperative camrelizumab and XELOX for locally advanced gastric or gastroesophageal junction adenocarcinoma
  di: Jiaxing He, et al.
  Pubblicazione: (2024)
• Efficacy and safety of PD‐L1 blockade envafolimab as neoadjuvant treatment in mismatch repair‐deficient, locally advanced colorectal cancer: An open‐label, single‐arm study
  di: Jiafeng Fang, et al.
  Pubblicazione: (2025)
• Phase I trial of apatinib and paclitaxel+oxaliplatin+5‐FU/levoleucovorin for treatment‐naïve advanced gastric cancer
  di: Shen Zhao, et al.
  Pubblicazione: (2024)
• Efficacy and safety of fruquintinib combined with albumin‐bound paclitaxel as second‐line therapy for advanced gastric cancer following failure of PD ‐1 inhibitor‐containing treatment ( TACTIC GC ‐01): A phase II single‐arm study
  di: Xiaoting Ma, et al.
  Pubblicazione: (2025)
• A prospective single‐center, single‐arm, open‐label, phase II study of sintilimab and anlotinib combined with chemotherapy in neoadjuvant treatment of resectable esophageal cancer
  di: Hongtao Duan, et al.
  Pubblicazione: (2024)